



PharmSource® Lead Sheet

New business opportunities for companies serving pharma

©2010 PharmSource Information Services Inc.

[Contact Information](#) [License Information](#)

FOR WEEK OF:

05-16-2010

[\[Export All\]](#) [\[Clear All\]](#)

Products in Development ●

Product Acquisitions ●

Corporate Finance ●

Other Sponsor Events ●

Key Appointments ●

Download

Preferences

Comments/Questions?

Full Database Search

Qualifying Info Search

[PRINTER FRIENDLY](#)

[\[Export All\]](#) [\[Clear All\]](#)

[Export help](#)

Julia's Profile

Products in Development

Preclinical

Export

Company: [Adamis Pharmaceuticals Corp.](#)

HQ Location: Del Mar, CA

Product: APC-100

Dosage Form: Unknown

Nature of API: Chemical - Normal potency

Therapeutic Area: Oncology - Other

Comment: Adamis plans to submit an IND in Q3 of 2010 for a clinical trial of APC-100 as a treatment for prostate cancer. The Phase I/IIa clinical trial will commence before the end of 2010.

Research contact: [Richard L. Aloj](#)

Research contact: [Thomas Moll, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [AMRI](#)

HQ Location: Albany, NY

Product: MCH-1 receptor antagonist

Dosage Form: Oral - Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Nutrition and obesity

Comment: AMRI expects to file an IND by the end of Q2 of 2010 for its MCH-1 receptor antagonist for the treatment of obesity. The candidate is a small molecule that has demonstrated good oral pharmacokinetics and efficacy in rodent models of obesity.

CMC R&D Contact: [Michael P. Trova, PhD](#)

Preclinical contact: [Bruce J. Sargent, PhD](#)

Manufacturing and packaging contact: [Steven R. Hagen, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Cytokinetics, Inc.](#)

HQ Location: South San Francisco, CA

Product: CK-2018571

Dosage Form: Aerosol spray

Nature of API: Chemical - Normal potency

Therapeutic Area: Anti-asthma

Pulmonary - Other

Comment: Cytokinetics reports preclinical data with CK-2018571 in models of bronchoconstriction. CK-2018571 was found to selectively inhibit the ATPase activity of smooth muscle myosin and relax methacholine-precontracted tracheal rings in a concentration-dependent manner. These results suggest that direct inhibition of smooth muscle myosin with CK-2018571 may be a possible treatment of chronic obstructive pulmonary disease and asthma.

Preclinical contact: [David J. Morgans, Jr., PhD](#)

Clinical research contact: [Andrew A. Wolff, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Cytokinetics, Inc.](#)

HQ Location: South San Francisco, CA

Product: CK-2019165

Dosage Form: Aerosol spray

Nature of API: Chemical - Normal potency

Therapeutic Area: Anti-asthma
Pulmonary - Other

Comment: Cytokinetics reports preclinical data with CK-2019165, an active prodrug of CK-2018571, in preclinical models of bronchoconstriction. CK-2019165 was found to inhibit methacholine-induced bronchoconstriction in two preclinical models of pulmonary function. The results suggest that direct inhibition of smooth muscle myosin with CK-2019165 may be a treatment for chronic obstructive pulmonary disease and asthma.

Corporate: [Robert I. Blum](#)

Clinical research contact: [Andrew A. Wolff, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Emergent BioSolutions](#)

HQ Location: Rockville, MD

Product: Anthrax antibody

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Monoclonal antibody

Therapeutic Area: Biodefense/Security

Comment: Emergent BioSolutions receives clearance of its IND for a therapeutic monoclonal anthrax antibody. A Phase I study that will evaluate the safety and pharmacokinetics of the anthrax antibody as a parenteral post-exposure therapy will commence shortly.

Manufacturing and packaging contact: [Kyle W. Keese](#)

Research contact: [W. James Jackson, PhD](#)

Research contact: [Stephen Lockhart](#)

[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Geron Corporation](#)**HQ Location:** Menlo Park, CA**Product:** GRNCM1**Dosage Form:** Parenteral - Unspecified**Nature of API:** Biologic -
Manipulated/Transplanted cells**Therapeutic Area:** Cardiovascular**Comment:** Geron reports positive preclinical data for GRNCM1, a potential treatment for heart failure. The injected cardiomyocyte product is derived from human embryonic stem cells. Data suggest the drug does not cause cardiac arrhythmias after transplantation into a chronic heart damage model. **Research contact:** [Jane S. Lebkowski, PhD](#) **Clinical research contact:** [Stephen M. Kelsey, MD](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [KemPharm, Inc.](#)**HQ Location:** North Liberty, IA**Product:** KP201**Dosage Form:** Oral - Unspecified**Nature of API:** Chemical - Controlled substance**Therapeutic Area:** Analgesic - Narcotic**Comment:** KemPharm plans to file an IND in H2 of 2010 for KP201 for the treatment of pain. KP201 is a prodrug candidate that is composed of hydrocodone combined with a ligand. **Research contact:** [Sven Guenther, PhD](#) **Research contact:** [Travis C. Mickle, PhD](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Omeros Corporation](#)**HQ Location:** Seattle, WA**Product:** MASP-2 candidate**Dosage Form:** Parenteral - Unspecified**Nature of API:** Biologic - Monoclonal antibody**Therapeutic Area:** Anti-inflammatory**Comment:** Omeros selects a clinical candidate from its mannan-binding lectin-associated serine protease-2 (MASP-2) program to treat disorders caused by complement activated inflammation. MASP-2 is a novel pro-inflammatory protein target in the complement system, a component of the immune system. The company has initiated the cGMP manufacturing development process to prepare for clinical trials of the fully human, high-affinity, blocking

antibody to MASP-2.

Research contact: [Clark E. Tedford, PhD](#)

Clinical research contact: [J. Steven Whitaker, MD, JD](#)

CMC R&D Contact: [Wayne R. Gombotz, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [RepliGen Corporation](#)

HQ Location: Waltham, MA

Product: RG2833

Dosage Form: Oral - Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Neurology

Comment: RepliGen files an IND for Phase I trials with RG2833, its histone deacetylase enzyme (HDAC) inhibitor to treat inherited neurodegenerative diseases such as Friedreich's ataxia. Preclinical data suggest that specific HDAC inhibitors increase the production of the protein frataxin, which may arrest disease progression in patients with Friedreich's ataxia.

Research contact: [James R. Rusche, PhD](#)

Research contact: [Stephen Tingley](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Senesco Technologies, Inc.](#)

HQ Location: New Brunswick, NJ

Product: SNS-01

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - DNA - Plasmid
Nucleic acid - RNA

Therapeutic Area: Oncology - Other

Comment: Senesco plans to initiate a Phase I trial with SNS-01 in multiple myeloma. SNS-01 consists of three components: an eIF5A plasmid, an siRNA against eIF5A and polyethyleneimine (PEI). The eIF5A plasmid upregulates the apoptotic pathways within cancer cells. The siRNA downregulates proinflammatory cytokines, NF-kB and ICAM, which are proliferation factors for multiple myeloma. PEI is a nanoparticle complexed to the other two components for intravenous delivery.

Research contact: [John E. Thompson, PhD](#)

Research contact: [Richard Dondero](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Stealth Peptides, Inc.](#)

HQ Location: Rockville, MD

Product: Bendavia

Dosage Form: Parenteral - Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Cardiovascular

Comment: Stealth Peptides receives IND approval to initiate a Phase I trial with Bendavia for the treatment of ischemia reperfusion injury. Bendavia is a new chemical entity that targets mitochondria and is delivered intravenously. The trial will enroll 40 patients.

Corporate: [Travis Wilson](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase I

Export

Company: [Achillion Pharmaceuticals, Inc.](#)

HQ Location: New Haven, CT

Product: ACH-1625

Dosage Form: Oral - Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Antiviral
Liver disease

Comment: Achillion expects to commence Phase II trials of ACH-1625 for the treatment of hepatitis C virus (HCV) infection over the next few months. In December 2009, the company reported positive data from a Phase Ib trial. The product is a highly selective inhibitor of the HCV NS3 protease.

Research contact: [Milind Deshpande, PhD](#)

Regulatory: [Gautam Shah, PhD](#)

Clinical research contact: [Elizabeth Olek](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Adeona Pharmaceuticals, Inc.](#)

HQ Location: Ann Arbor, MI

Product: Zinthionein ZC

Dosage Form: Tablet - Controlled release

Nature of API: Chemical - Normal potency
Peptide - Process unknown

Therapeutic Area: Alzheimer's disease/Dementia

Comment: Adeona recently reported positive results from the first part of a Phase I trial with Zinthionein ZC for the treatment of Alzheimer's disease or mild cognitive impairment. Zinthionein ZC is a once-daily, gastroretentive, sustained-release, oral tablet formulation of zinc and cysteine. The second part of the Phase I trial is ongoing, with plans to enroll 60 Alzheimer's disease and mild cognitive impairment patients.

Research contact: [David A. Newsome, MD](#)

Research contact: [Lisa Jo Abbo, MHA](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Cerenis Therapeutics](#)

HQ Location: [Multiple](#)

Product: CER-001

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Recombinant protein

Therapeutic Area: Cardiovascular

Comment: Cerenis reports positive data from a Phase I trial with CER-001 for the treatment of cardiovascular disease. CER-001 is a complex of human ApoA-I and phospholipids, which is designed to mimic HDL.

Research contact: [Narendra Lalwani, PhD](#)

Research contact: [Cynthia Sundell, PhD](#)

CMC R&D Contact: [Daniela Carmen Oniciu, PhD](#)

Research contact: [Ronald Barbaras, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Chimerix, Inc.](#)

HQ Location: Durham, NC

Product: CMX157

Dosage Form: Oral solid

Nature of API: Chemical - Normal potency

Therapeutic Area: Antiviral

Comment: Chimerix initiates a Phase I trial with CMX157 for the treatment of HIV. The product is orally bioavailable in rats and is a hexadecyloxypropyl ester of tenofovir.

Clinical research contact: [Gwendolyn Painter, MD](#)

CMC R&D Contact: [Merrick R. Almond, PhD](#)

Research contact: [Rosemary O'Mahony, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [iCo Therapeutics Inc](#)

HQ Location: Vancouver, BC, Canada

Product: iCo-007

Dosage Form: Parenteral - Unspecified

Nature of API: Nucleic acid - Oligonucleotide

Therapeutic Area: Ophthalmology
Diabetes

Comment: iCo reports positive data from Phase I trials of iCo-007, a treatment for diabetic macular edema. Delivered via intravitreal injection, iCo-007 targets c-Raf kinase messenger RNA. The product was licensed from Isis Pharmaceuticals in 2005.

Research contact: [Santa Jeremy Ono, PhD](#)

Clinical research contact: [Peter Hnik, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Inhibitex, Inc.](#)

HQ Location: Alpharetta, GA
Product: INX-189
Dosage Form: Oral – Unspecified
Nature of API: Chemical - Normal potency
Therapeutic Area: Antiviral
Liver disease

Comment: Inhibitex initiates a Phase I trial with INX-189, a treatment for hepatitis C virus infections. The drug is an HCV nucleotide polymerase inhibitor that is delivered orally.

- Research contact:** [John Vernachio, PhD](#)
- Research contact:** [Joseph Patti, PhD](#)
- Research contact:** [Geoffrey W. Henson, Ph.D.](#)
- CMC R&D Contact:** [Stan Chamberlain, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Mesoblast Limited](#)

HQ Location: Melbourne, VIC, Australia

Product: NeoFuse

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic -
Manipulated/Transplanted cells

Therapeutic Area: Other

Comment: Mesoblast receives FDA clearance to begin a Phase II trial with NeoFuse for fusion of the cervical spine in the neck. NeoFuse is an allogeneic stem cell product which is surgically implanted. The trial will include 36 patients in the US and Australia.

Corporate: [Suzanne Lipe](#)

Clinical research contact: [James T. Ryaby, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Myriad Pharmaceuticals, Inc.](#)

HQ Location: Salt Lake City, UT

Product: MPC-3100

Dosage Form: Oral – Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Oncology - Other

Comment: Myriad expects to complete and report final results in H2 of 2010 for a Phase I trial with MPC-3100 for the treatment of cancer. MPC-3100 is a fully synthetic, orally bioavailable, small molecule inhibitor of heat shock protein 90.

Clinical research contact: [Edward Swabb, MD, PhD](#)

Clinical research contact: [Maryse R. Brulotte](#)

Clinical research contact: [Andrew Beelen, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [RegeneRx Biopharmaceuticals, Inc.](#)

HQ Location: Rockville, MD
Product: RGN-352 (Thymosin beta 4 IV)
Dosage Form: Parenteral - Unspecified
Nature of API: Peptide - Chemical
Therapeutic Area: Cardiovascular
Comment: RegeneRx plans to commence a Phase II trial of RGN-352 for the treatment of acute myocardial infarction later in 2010. The company reported positive Phase I trial results in October 2009. RGN-352 is an injectable formulation of Tβ4, a synthetic version of a naturally occurring peptide.

Corporate: [J.J. Finkelstein](#)

Clinical research contact: [David R. Crockford](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Roche](#)
HQ Location: Basel, Switzerland
Product: TB-403 (anti-PIGF)
Dosage Form: Parenteral - Unspecified
Nature of API: Biologic - Monoclonal antibody
Therapeutic Area: Oncology - Immunotherapy
Comment: Roche initiates a dose-finding imaging study with TB-403 in patients with metastatic treatment-refractory colorectal and ovarian cancers. TB-403 is a humanized monoclonal antibody that blocks the formation of new blood vessels in solid tumors, reducing the growth and spread of cancer cells. Roche licensed the global right to TB-403 from ThromboGenics and BioInvent.

Research contact: [Daniel O'Day](#)

Research contact: [Richard Scheller](#)

Research contact: [Jean-Jacques Garaud, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase II

Export

Company: [Mpex Pharmaceuticals](#)
HQ Location: San Diego, CA
Product: Aeroquin (MP-376)
Dosage Form: Aerosol spray
Nature of API: Chemical - Antibiotic
Therapeutic Area: Antibacterial
Pulmonary - Other
Comment: Mpex receives FDA clearance to initiate Phase III trials with Aeroquin for the treatment of bacterial pulmonary infections in patients with cystic fibrosis (CF). Aeroquin is an aerosolized formulation of the antibiotic levofloxacin. The product has orphan drug designation for CF.

Clinical research contact: [Jeffrey Loutit](#)

Research contact: [Michael N. Dudley](#)

[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Neotropix](#)**HQ Location:** Malvern, PA**Product:** NTX-010 (SVV-001)**Dosage Form:** Parenteral - Liquid**Nature of API:** Other**Therapeutic Area:** Oncology - Other**Comment:** Neotropix is currently enrolling patients in a Phase II trial of NTX-010 for the treatment of neuroendocrine tumors. The product is a tumor-selective naturally occurring oncolytic picornavirus that is not genetically modified. NTX-010 previously received orphan drug designation from the FDA for the treatment of neuroendocrine tumors. NTX-010 is distributed as a single dose vial consisting of virus and excipients suspended in saline. **Corporate:** [Peter Lanciano](#) **Research contact:** [Kevin Burroughs](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Neovacs SA](#)**HQ Location:** Paris, France**Product:** TNF α Kinoid**Dosage Form:** Parenteral - Unspecified**Nature of API:** Biologic - Protein**Therapeutic Area:** Dermatology
Gastrointestinal
Anti-inflammatory
Immunomodulator**Comment:** Neovacs completes enrollment in a Phase I/II trial with TNF α Kinoid in patients with Crohn's disease. The drug consists of a conjugate of inactivated TNF α to a carrier protein, keyhole limpet hemocyanin. The therapeutic vaccine is in development to treat TNF α -dependent autoimmune diseases such as rheumatoid arthritis, Crohn's disease and psoriasis. A Phase IIa trial of TNF α Kinoid in patients with rheumatoid arthritis is ongoing. **CMC R&D Contact:** [Bernard Fanget](#) **Clinical research contact:** [Pierre Vandepapeliere, MD, PhD](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Revotar Biopharmaceuticals](#)**HQ Location:** Hennigsdorf, Germany**Product:** Bimosiamose**Dosage Form:** Semi-solid - Non-sterile
Liquid - Non-sterile**Nature of API:** Chemical - Normal potency**Therapeutic Area:** Dermatology

Anti-asthma
Pulmonary - Other

Comment: Revotar reports positive data from a Phase IIa trial with nebulized bimosiamose solution for patients with chronic obstructive pulmonary disease. The trial took place in Germany and included 18 patients. The product previously received orphan drug status from the EMA. Bimosiamose is a pan-selectin antagonist. The candidate is also in trials for patients with asthma and as a cream for chronic plaque-type psoriasis.

Corporate: [Martin Pöhlchen](#)

Corporate: [Ludwig Felber](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Rexahn Pharmaceuticals](#)

HQ Location: Rockville, MD

Product: Zoraxel

Dosage Form: Tablet - Immediate release

Nature of API: Chemical - Normal potency

Therapeutic Area: Andrology

Comment: Rexahn plans to conduct a Phase IIb trial of Zoraxel for the treatment of erectile dysfunction in H2 of 2010. In May 2009, Rexahn reported positive preliminary data from a Phase II trial for the same indication. Zoraxel is a dual serotonin and dopamine enhancer in the brain, where neurotransmitters play a key role in sexual functions of sexual motivation and arousal, erection and release. The Phase IIb study will include 225 subjects between the ages of 18 and 65 and will be conducted at multiple sites in the US.

Corporate: [Tae Heum \(Ted\) Jeong](#)

Corporate: [Rick Soni](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Tranzyme Pharma](#)

HQ Location: [Multiple](#)

Product: TZP-101 (Ulimorelin)

Dosage Form: Parenteral - Liquid

Nature of API: Chemical - Normal potency

Therapeutic Area: Gastrointestinal

Comment: Tranzyme plans to initiate a Phase III trial with TZP-101 for the treatment of postoperative ileus. TZP-101 is a novel ghrelin agonist; ghrelin is an endogenous peptide known to stimulate gastric motility. The compound has fast track designation from the FDA. The company previously reported positive Phase II trial results with TZP-101 for the treatment of

gastroparesis.

- Clinical research contact:** [Gordana Kosutic, MD](#)
- Preclinical contact:** [Helmut Thomas, PhD](#)
- Corporate:** [Mark L. Peterson, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Phase III

Export

Company: [ARCA biopharma, Inc.](#)

HQ Location: Broomfield, CO

Product: Bucindolol hydrochloride (Gencaro)

Dosage Form: Tablet

Nature of API: Chemical - Normal potency

Therapeutic Area: Cardiovascular

Comment: ARCA reaches an agreement with the FDA for a Special Protocol Assessment on the design of a Phase III trial of bucindolol in patients with chronic heart failure. Bucindolol is a beta-blocker and mild vasodilator that has fast track designation from the FDA for the treatment of chronic heart failure. ARCA received a Complete Response Letter from the FDA in June 2009 regarding its NDA for bucindolol.

Corporate: [Michael R. Bristow, MD, PhD](#)

Corporate: [Patrick M. Wheeler](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Chelsea Therapeutics, Inc.](#)

HQ Location: Charlotte, NC

Product: NORTHERA (droxidopa)

Dosage Form: Capsule

Nature of API: Chemical - Normal potency

Therapeutic Area: Antihypertensive
Neurology

Comment: Chelsea Therapeutics reports positive data from a third Phase III with NORTHERA for the treatment of symptomatic neurogenic orthostatic hypotension. NORTHERA is a synthetic catecholamine, a precursor of norepinephrine, a neurotransmitter used by sympathetic autonomic neurons that sends signals to the blood vessels and the heart.

Corporate: [Joseph Oliveto](#)

Research contact: [L. Arthur Hewitt, PhD](#)

Research contact: [Cameron B. Szakacs, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Omeros Corporation](#)

HQ Location: Seattle, WA

Product: OMS103HP
Dosage Form: Parenteral - Liquid
Parenteral - Lyophilized
Nature of API: Chemical - Normal potency
Therapeutic Area: Other
Anti-inflammatory
Comment: Omeros expects to report results from Phase III trials of a lyophilized form of OMS103HP for the improvement in knee function following arthroscopic anterior cruciate ligament (ACL) reconstruction. The OMS103HP product is added to standard irrigation solutions and perfused through the joint during arthroscopic ACL surgery. A liquid form OMS103HP is also being developed.

Research contact: [Clark E. Tedford, PhD](#)

Clinical research contact: [J. Steven Whitaker, MD, JD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Terminated in Phase II or III

Export

Company: [Avexa](#)

HQ Location: Richmond, VIC, Australia

Product: Apricitabine (ATC)

Dosage Form: Oral solid

Nature of API: Chemical - Normal potency

Therapeutic Area: Antiviral

Comment: Avexa terminates development of apricitabine as a treatment for HIV after a development partner was not found. Apricitabine is a nucleoside reverse transcriptase inhibitor.

Research contact: [Jonathan Coates, PhD](#)

Research contact: [John Deadman, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Merck and Company, Inc.](#)

HQ Location: Whitehouse Station, NJ

Product: MK-2578

Dosage Form: Parenteral - Unspecified

Nature of API: Biologic - Protein

Therapeutic Area: Coagulation and blood formation

Comment: Merck terminates development of MK-2578, a pegylated form of erythropoietin. MK-2578 is a follow-on biologic similar to Amgen's Aranesp.

Clinical research contact: [Michael Rosenblatt](#)

Research contact: [Peter S. Kim, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Teva Pharmaceutical Industries Ltd.](#)

HQ Location: [Multiple](#)

Product: Talampanel
Dosage Form: Tablet
Nature of API: Chemical - Normal potency
Therapeutic Area: Neurology
Comment: Teva stops development of talampanel after negative Phase II trial results. Talampanel is a selective AMPA antagonist that was being developed as a potential treatment for patients with amyotrophic lateral sclerosis (ALS).

Research contact: [Ben-Zion Weiner, PhD](#)

Corporate: [Itzhak Krinsky](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Approved

Export

Company: [Roxro Pharma, Inc.](#)

HQ Location: Menlo Park, CA

Product: Sprix (ROX-888)

Dosage Form: Aerosol spray

Nature of API: Chemical - Normal potency

Therapeutic Area: Analgesic - Non-narcotic
Anti-inflammatory

Comment: Roxro receives FDA approval for Sprix for the short-term management of acute pain. Sprix is an intranasal formulation of ketorolac, a nonsteroidal anti-inflammatory drug.

Corporate: [Gayle Mills](#)

Research contact: [Roger Whiting, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Marketed

Export

Company: [Octapharma AG](#)

HQ Location: [Multiple](#)

Product: Wilate

Dosage Form: Parenteral - Lyophilized

Nature of API: Biologic - Blood derivative
Biologic - Protein

Therapeutic Area: Anticoagulant

Comment: Octapharma launches Wilate in the US for the treatment of spontaneous or trauma-induced bleeding episodes in patients with all types of von Willebrand disease. Wilate is a human plasma-derived, sterile, high-purity, double virus-inactivated human von Willebrand factor and coagulation Factor VIII concentrate.

Corporate: [Flemming Nielsen](#)

Corporate: [Tobias Marquerre](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Product Acquisitions & Alliances

Export

Buyer: [Pfizer, Inc.](#)

Seller: [Ergonex Pharma GmbH](#)

Transaction Type: Acquisition

Product: Terguride

Dosage Form: Oral - Unspecified

Nature of API: Chemical - Normal potency

Therapeutic Area: Cardiovascular
Pulmonary - Other

Development Phase: Phase II

Comment: Pfizer acquires the global (excluding Japan) rights to Ergonex's terguride, a pulmonary arterial hypertension drug. Pfizer will fund the remaining mid-stage trials of terguride. Ergonex will receive milestones and royalties. Terguride is already approved in Japan as a treatment for hyperprolactinemia, a hormone disorder that can cause infertility. Terguride has orphan drug status in the US and the European Union. Further terms of the deal were not disclosed.

Sourcing and Supply Chain contact: [Rick Connell](#)

Sourcing and Supply Chain contact: [Kyle Blair](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Corporate Finance, Alliances, and Acquisitions

Corporate Finance

Export

Company: [Afraxis](#)

HQ Location: San Diego, CA

Financing Type: Venture capital investment

Amount Raised: \$1.20 million

Description: Afraxis raises \$1.2 million toward a \$6 million equity round. The use of proceeds was not disclosed.

Strategy: Afraxis develops drugs to treat central nervous system disorders.

Research contact: [David Campbell](#)

Corporate: [Jay Lichter](#)

Preclinical contact: [Sergio Duron, PhD](#)

Research contact: [Ben Vollrath, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [AgeneBio](#)

HQ Location: Indianapolis, IN

Financing Type: Venture capital investment

Amount Raised: \$0.30 million

Description: AgeneBio raises \$300,000 from BioCrossroads' Indiana Seed Fund. Allocation of funds was not disclosed.

Strategy: AgeneBio focuses on the development of therapeutic products for Alzheimer's disease,

dementia and other memory disorders.

Corporate: [Tim Parshall](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Alexza Pharmaceuticals](#)

HQ Location: Mountain View, CA

Financing Type: Private equity placement

Amount Raised: \$1.01 million

Description: Alexza raises just over \$1 million in a private placement. Allocation of funds was not disclosed.

Strategy: Alexza focuses on the development and commercialization of novel products for the treatment of acute and intermittent conditions.

Research contact: [James Cassella, PhD](#)

Manufacturing and packaging contact: [Joseph L. Baker](#)

Manufacturing and packaging contact: [Michael Simms](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Avanir Pharmaceuticals, Inc.](#)

HQ Location: Aliso Viejo, CA

Financing Type: Secondary public offering

Amount Raised: \$27.50 million

Description: Avanir raises \$27.5 million in an underwritten public offering. Proceeds will be used for working capital.

Strategy: Avanir develops human monoclonal antibodies for infectious diseases and small molecules to treat central nervous system disorders and inflammatory diseases.

Corporate: [Keith Katkin](#)

Clinical research contact: [Randall E. Kaye, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [BioInvent](#)

HQ Location: Lund, Sweden

Financing Type: Milestone payment

Amount Raised: Unknown

Description: BioInvent and ThromboGenics receive a \$12.4 million milestone payment under an agreement with Roche due to the initiation of an imaging study with the anticancer antibody TB-403 in patients with metastatic treatment-refractory colorectal and ovarian cancer.

Strategy: BioInvent develops antibody drugs to target diseases with unmet clinical need.

Research contact: [Steven Glazer](#)

Regulatory: [Per-Anders Johansson](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Company:

Export

[BioProtein Technologies](#)

HQ Location: Jouy-en-Josas, France
Financing Type: Venture capital investment
Amount Raised: \$0.66 million
Description: BioProtein Technologies raises \$660,000 from existing investors. Funds will be used to develop a therapeutic protein for the prevention and treatment of septic shock.
Strategy: BioProtein Technologies produces human therapeutic proteins and vaccines in the milk of transgenic rabbits.

Research contact: [Pierre-Jean Ripoll, PhD](#)

Corporate: [Alexandre Fouassier](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [BioTime Inc.](#)

HQ Location: Alameda, CA
Financing Type: Private equity placement
Amount Raised: \$8.00 million
Description: BioTime receives \$8 million after two investors exercise their stock purchase warrants. Allocation of funds was not disclosed.
Strategy: BioTime develops and markets research products in the field of stem cells and regenerative medicine.

Corporate: [Judith Segall](#)

Research contact: [Hal Sternberg, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [CBio Limited](#)

HQ Location: [Multiple](#)
Financing Type: Private equity placement
Amount Raised: \$10.80 million
Description: CBio receives \$10.8 million from a convertible loan agreement. The funding provides working capital needed to complete a current Phase II clinical trial as well as resources for development activities planned in 2011.
Strategy: CBio Limited develops treatments for inflammatory and autoimmune disorders.

Corporate: [Jason Yeates](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [DARA BioSciences, Inc.](#)

HQ Location: Raleigh, NC
Financing Type: Secondary public offering
Amount Raised: \$10.00 million
Description: DARA plans to raise up to \$10 million in an underwritten public offering. Proceeds will be used for ongoing development of DARA's pipeline and working capital.
Strategy: DARA focuses its therapeutic development efforts on small

molecules, from late preclinical development through Phase II clinical trials, including candidates for the treatment of pain and metabolic diseases.

Corporate: [Richard Franco](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Deciphera Pharmaceuticals](#)

HQ Location: Lawrence, KS

Financing Type: Government grant

Amount Raised: \$0.39 million

Description: Deciphera receives a \$390,000 grant from the Kansas Bioscience Authority. Funds will be used to develop candidates for the treatment of cancer and autoimmune disorders.

Strategy: Deciphera Pharmaceuticals develops small molecule drugs that correct the molecular causes of disease brought about by badly regulated proteins.

Corporate: [Daniel Flynn, Ph.D.](#)

Clinical research contact: [Usha M. Rafferty](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Gemin X Pharmaceuticals](#)

HQ Location: Monteval, QC, Canada

Financing Type: Venture capital investment

Amount Raised: \$3.90 million

Description: Gemin X raises \$3.9 million toward an \$8.5 million round of equity and rights. The use of proceeds was not disclosed.

Strategy: Gemin X Pharmaceuticals targets the discovery and development of advanced oncology therapeutics based on the manipulation of apoptosis.

Clinical research contact: [Jean Viallet, MD](#)

Clinical research contact: [Mark Berger, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Ikaria Holdings, Inc.](#)

HQ Location: Clinton, NJ

Financing Type: IPO filed

Amount Raised: Unknown

Description: Ikaria files an IPO to raise up to \$200 million. The proceeds will repay a portion of debt and provide funding for general corporate purposes, including the development of product candidates, foreign expansion and acquisition, and in-licensing opportunities.

Strategy: Ikaria discovers, develops and delivers therapies in the critical care arena.

Research contact: [Ralf Rosskamp, MD](#)

Corporate: [Stephen Ross](#)

[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Intarcia Therapeutics, Inc.](#)**HQ Location:** Hayward, CA**Financing Type:** Venture capital investment**Amount Raised:** \$14.50 million**Description:** Intarcia raises \$14.5 million in a round of equity, debt, rights and securities. The use of proceeds was not disclosed.**Strategy:** Intarcia Therapeutics develops therapies for the treatment of cancer, as well as immunological and infectious diseases. **Research contact:** [Thomas Alessi, PhD](#) **Research contact:** [Janice Dahms](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [iTherX Pharmaceuticals Inc.](#)**HQ Location:** San Diego, CA**Financing Type:** Venture capital investment**Amount Raised:** \$2.80 million**Description:** iTherX raises \$2.8 million in a Series A-1 round of financing. The use of proceeds was not disclosed.**Strategy:** iTherX Pharmaceuticals develops antiviral products. **Research contact:** [Flossie Wong-Staal, PhD](#) **Clinical research contact:** [Barney King](#) **Corporate:** [Mike Lack](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Lentigen](#)**HQ Location:** Gaithersburg, MD**Financing Type:** Government grant**Amount Raised:** Unknown**Description:** Lentigen receives a grant from the NIH for a program on lentiviral gene therapy for mucopolysaccharidosis.**Strategy:** Lentigen develops and manufactures lentiviral vectors. **Research contact:** [Boro Dropulic, PhD](#) **Corporate:** [Tim Ravenscroft](#)[Print Lead](#)[Email Lead](#)[\[Back to Top\]](#) Export**Company:** [Mesoblast Limited](#)**HQ Location:** Melbourne, VIC, Australia**Financing Type:** Private equity placement**Amount Raised:** \$32.50 million**Description:** Mesoblast raises \$32.5 million. Funds will be used for Mesoblast's planned acquisition of Angioblast Systems and for working capital.**Strategy:** Mesoblast develops therapies for patients with bone and joint diseases. **Corporate:** [Suzanne Lipe](#)

Clinical research contact: [James T. Ryaby, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [NanoViricides, Inc.](#)

HQ Location: West Haven, CT

Financing Type: Private equity placement

Amount Raised: \$5.00 million

Description: NanoViricides raises \$5 million in a registered shelf offering. The plans for proceeds were not disclosed.

Strategy: NanoViricides discovers, develops and commercializes therapeutics (nanoviricides) to advance the care of patients suffering from life-threatening viral infections.

Corporate: [Eugene Seymour, MD, PhD](#)

Research contact: [Randall Barton, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [NuPathe](#)

HQ Location: Conshohocken, PA

Financing Type: IPO filed

Amount Raised: Unknown

Description: NuPathe files an IPO to raise up to \$86.25 million. Funds will be used for the development and commercialization of Zelrix and preclinical and clinical development of NP201 and NP202.

Strategy: NuPathe specializes in the acquisition and development of therapeutic products in the area of neuroscience.

Corporate: [Terri B. Sebree](#)

Research contact: [Mark W. Pierce](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Pharmasset, Inc.](#)

HQ Location: Princeton, NJ

Financing Type: Secondary public offering

Amount Raised: \$101.10 million

Description: Pharmasset raises \$101.1 million in an underwritten public offering. The proceeds will support general corporate purposes, which may include the funding of clinical trials, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property and the acquisition of assets or businesses.

Strategy: Pharmasset develops small molecule therapeutics to treat viral infections and cancer.

Research contact: [Michael J. Otto, PhD](#)

Clinical research contact: [M. Michelle Berrey, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Plethora Solutions](#)

HQ Location: London, UK

Financing Type: Mixed financing

Amount Raised: \$0.80 million

Description: Plethora Solutions raises \$800,000 through the issuance of convertible loan notes and the private placement of ordinary shares. Allocation of funds was not disclosed.

Strategy: Plethora develops products for the treatment and management of urological disorders.

Corporate: [Steven Powell](#)

Research contact: [Michael Wyllie](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Pro-Pharmaceuticals, Inc.](#)

HQ Location: Newton, MA

Financing Type: Private equity placement

Amount Raised: \$0.57 million

Description: Pro-Pharmaceuticals raises \$570,000 through a private placement. Funds will be used to commercialize DAVANAT.

Strategy: Pro-Pharmaceuticals develops carbohydrate chemistry-based targeted cancer therapeutics.

Corporate: [Maureen E. Foley](#)

Manufacturing and packaging contact: [Eliezer Zomer, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Protalix Biotherapeutics](#)

HQ Location: Carmiel, Israel

Financing Type: Government grant

Amount Raised: \$4.10 million

Description: Protalix receives \$4.1 million from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor. Funds will be used for preclinical and clinical development of the company's pipeline.

Strategy: Protalix focuses on efficient, large-scale production of complex human therapeutic proteins using its proprietary plant cell culture technology and innovative bioreactor system.

Research contact: [Yoseph Shaaltiel, PhD](#)

Research contact: [Einat Brill Almon, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [RegeneRx Biopharmaceuticals, Inc.](#)

HQ Location: Rockville, MD

Financing Type: Government grant

Amount Raised: \$3.00 million

Description:

RegeneRx receives a \$3 million grant from the NIH to support the

clinical development of RGN-352, a therapeutic for acute myocardial infarction.

Strategy: RegeneRx Biopharmaceuticals develops thymosin beta 4 (TB4) for the healing of chronic wounds caused by disease, abrasion or other pathology.

Corporate: [J.J. Finkelstein](#)

Clinical research contact: [David R. Crockford](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [ThromboGenics, Ltd](#)

HQ Location: [Multiple](#)

Financing Type: Milestone payment

Amount Raised: Unknown

Description: ThromboGenics shares with BioInvent a \$12.4 million milestone from Roche, after Roche initiated a dose-ranging study with TB-403.

Strategy: ThromboGenics focuses on the development of therapeutics for conditions related to the vascular system.

Clinical research contact: [Steve Pakola, MD](#)

CMC R&D Contact: [Phil Challis](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Corporate Alliances

Export

Alliance Partners: [Transgene](#) [Tianjin Tasly Pharmaceutical Co. Ltd.](#)

Description: Transgene and Tianjin Tasly Pharma establish a joint venture in China that will focus on developing biological drugs. Each company will contribute \$146,000 and own a 50% stake in the joint venture.

Manufacturing and packaging contact: [Remi Gloeckler](#)

Research contact: [Jean-Yves Bonnefoy, PhD](#)

Corporate: [Naifeng Wu](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Corporate Acquisitions

Export

Buyer: [Astellas Pharma, Inc.](#)

HQ Location: [Multiple](#)

Seller: [OSI Pharmaceuticals Inc.](#)

HQ Location: Melville, NY

Amount: \$4.00 billion

Description: OSI agrees to be acquired by Astellas for \$4 billion in an all-cash transaction.

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Buyer: [Victory Pharma](#)

HQ Location: San Diego, CA

Seller: [MiddleBrook Pharmaceuticals, Inc.](#)

HQ Location: Westlake, TX
Amount: \$17.10 million
Description: Victory Pharma purchases substantially all of the assets of MiddleBrook. MiddleBrook filed for bankruptcy protection at the end of April 2010.

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Other Sponsor Events

Export

Sponsor: [3-V Biosciences](#)

HQ Location: [Multiple](#)

Event Location: Menlo Park, CA

Strategy: 3-V Biosciences discovers and develops antiviral therapeutics that target the host cell factors required for viral infection.

Description: 3-V opens its 20,000 square-foot headquarters and laboratory facility in Menlo Park, CA. The site will accommodate expanded medicinal chemistry, biology and pharmacology, as well as target discovery and validation activities.

Research contact: [Robert S. McDowell, PhD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Bayer Corp.](#)

HQ Location: [Multiple](#)

Event Location: San Francisco, CA

Strategy: Bayer discovers and develops novel drugs for the treatment of various ailments.

Description: Bayer will open a US Innovation Center in San Francisco and move 65 researchers there.

Research contact: [Terry Hermiston](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Derma Sciences, Inc.](#)

HQ Location: Princeton, NJ

Event Location: London, UK

Strategy: Derma Sciences focuses on wound care medical devices and pharmaceuticals.

Description: Derma Sciences establishes an international subsidiary, Derma Sciences Europe Limited, and will soon be opening an office near London, UK.

Corporate: [Frederic Eigner](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Pfizer, Inc.](#)

HQ Location: New York, NY

Event Location: Worldwide

Strategy: Pfizer develops and commercializes a wide array of products for various medical

conditions.

Description: Pfizer plans to close 8 manufacturing plants and reduce operations at 6 more resulting in 6,000 job cuts globally in the next several years.

Sourcing and Supply Chain contact: [Mac Lynch](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Sponsor: [Takeda Pharmaceuticals North America, Inc.](#)

HQ Location: Deerfield, IL

Event Location: Deerfield, IL

Strategy: Takeda discovers, develops, manufactures and markets a broad range of pharmaceutical products.

Description: Takeda plans to reduce its staff by more than 1,400 employees in its US operations. In Chicago, 28% of the 1,300 positions at its headquarters in Deerfield, IL will be affected. The Takeda Global R&D Center expects to cut 20% of its 840 employees.

Clinical research contact: [Stuart Kupfer, MD](#)

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Key Appointments

Export

Company: [3-V Biosciences](#)

HQ Location: [Multiple](#)

Appointee: Robert S. McDowell, PhD

Position: VP, Research

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Epizyme Corporation](#)

HQ Location: Cambridge, MA

Appointee: Mikel Moyer, PhD

Position: VP, Molecular Discovery

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Infinity Pharmaceuticals Inc.](#)

HQ Location: Cambridge, MA

Appointee: Vito J. Palombella, PhD

Position: CSO

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Morphotek, Inc.](#)

HQ Location: Exton, PA

Appointee: Joye L. Bramble, PhD

Position: VP, Pilot Plant Operations

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Radient Pharmaceuticals Corporation](#)

HQ Location: Tustin, CA

Appointee: Afsaneh Motamed-Khorasani

Position: Director, Oncology

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)

Export

Company: [Xenon Pharmaceuticals](#)

HQ Location: Burnaby, BC, Canada

Appointee: Tarek S. Mansour, PhD

Position: EVP, R&D

[Print Lead](#)

[Email Lead](#)

[\[Back to Top\]](#)